logo

For the Inventor, By the Inventor

Osaka, Japan

Shin-ichi Hamano

This inventor holds 6 USPTO granted patents. Top assignees: Ono Pharmaceutical Co., Ltd., Katsuhiko Mikoshiba. Active years: 1997-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shin-ichi Hamano. Retrieved from https://idiyas.com/inventor/shin-ichi-hamano

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 6

% Patents Active = 50.0

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 58(Granted Patents)


Location History:

  • Osaka, JP (1997 - 2007)
  • Mishima-gun, JP (2006 - 2007)

Company Filing History:

goldMedal5 out of 575 
 
Ono Pharmaceutical Co., Ltd.
 patents
silverMedal1 out of 1 
 
Katsuhiko Mikoshiba
 patent

Years Active: 1997-2007

Loading Chart...
6 patents (USPTO):Explore Patents
1. 7262193 - Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient (2007-08-28),
2. 7217701 - Intracellular calcium concentration increase inhibitors (2007-05-15),
3. 7119091 - Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient (2006-10-10),
4. 7053090 - Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient (2006-05-30),
5. 5698590 - Prostaglandin derivatives (1997-12-16),
6. 5690957 - Prostaglandin derivatives (1997-11-25),

Title: Innovations and Contributions of Inventor Shin-ichi Hamano

Introduction

Shin-ichi Hamano is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of 6 patents. His work focuses on innovative compounds that have the potential to treat various inflammatory diseases and other health conditions.

Latest Patents

Among his latest patents is the development of Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions that utilize these compounds as active ingredients. These derivatives are designed to regulate the effects of chemokines and chemokine receptors, making them useful in the prevention and treatment of a range of inflammatory diseases, including asthma, atopic dermatitis, and rheumatoid arthritis. Another significant patent involves an intracellular calcium concentration increase inhibitor, which contains a boron compound as the active ingredient. This compound is deemed beneficial for treating conditions such as ischemic diseases, immune deficiency diseases, and Alzheimer's disease.

Career Highlights

Throughout his career, Shin-ichi Hamano has worked with prominent companies, including Ono Pharmaceutical Co., Ltd. His innovative research and development efforts have led to advancements in pharmaceutical compositions that address critical health issues.

Collaborations

Shin-ichi has collaborated with esteemed colleagues such as Shiro Shibayama and Hiromu Habashita, contributing to the advancement of pharmaceutical sciences.

Conclusion

Shin-ichi Hamano's contributions to the field of pharmaceuticals through his innovative patents highlight his role as a significant inventor. His work continues to impact the treatment of various health conditions, showcasing the importance of innovation in medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…